tafamidis meglumine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Conditions
Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Trial Timeline
Apr 28, 2021 → Feb 12, 2023
NCT ID
NCT04828993About tafamidis meglumine
tafamidis meglumine is a approved stage product being developed by Pfizer for Transthyretin Amyloid Polyneuropathy (ATTR-PN). The current trial status is completed. This product is registered under clinical trial identifier NCT04828993. Target conditions include Transthyretin Amyloid Polyneuropathy (ATTR-PN).
What happened to similar drugs?
2 of 18 similar drugs in Transthyretin Amyloid Polyneuropathy (ATTR-PN) were approved
Approved (2) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04828993 | Approved | Completed |
Competing Products
20 competing products in Transthyretin Amyloid Polyneuropathy (ATTR-PN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 39 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Tafamidis | Pfizer | Pre-clinical | 30 |
| Fx-1006A | Pfizer | Phase 2 | 35 |
| Tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 26 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 26 |
| Vyndaqel | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis | Pfizer | Approved | 43 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 30 |